(Rac)-Plevitrexed is primarily investigated for its potential in cancer treatment, particularly in targeting solid tumors. It functions as a thymidylate synthase inhibitor, which disrupts DNA synthesis in rapidly dividing cancer cells, thereby inhibiting their growth. This compound has been explored in clinical trials for its efficacy in treating various cancers, including colorectal, pancreatic, and non-small cell lung cancer. Its role in combination therapies is also being studied to enhance the overall effectiveness of chemotherapy regimens. Research continues to evaluate its safety profile and therapeutic potential in improving patient outcomes.